Gennex Laboratories Ltd
BSE:531739
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ferrexpo PLC
LSE:FXPO
|
CH |
|
S
|
Suzhou Everbright Photonics Co Ltd
SSE:688048
|
CN |
|
H
|
Hunan Heshun Petroleum Co Ltd
SSE:603353
|
CN |
|
Magellanic Cloud Ltd
BSE:538891
|
IN |
|
Zhejiang Reclaim Construction Group Co Ltd
SZSE:002586
|
CN |
|
N
|
NK Rosneft' PAO
LSE:ROSN
|
RU |
Gennex Laboratories Ltd
Note Receivable
Gennex Laboratories Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gennex Laboratories Ltd
BSE:531739
|
Note Receivable
₹10.6m
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Note Receivable
₹3.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Note Receivable
₹5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
59%
|
CAGR 10-Years
7%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Note Receivable
₹2.6B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Note Receivable
₹504.1m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-16%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Note Receivable
₹2.4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
25%
|
CAGR 10-Years
2%
|
|
Gennex Laboratories Ltd
Glance View
Gennex Laboratories Ltd. engages in the manufacture of bulk drugs and intermediates products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing of bulk drugs, intermediaries and biotech products. The firm has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The firm operates through Pharmaceutical Products (Bulk Drugs) segment. The firm's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The firm has manufacturing facilities in India which caters to both domestic and international markets.
See Also
What is Gennex Laboratories Ltd's Note Receivable?
Note Receivable
10.6m
INR
Based on the financial report for Dec 31, 2025, Gennex Laboratories Ltd's Note Receivable amounts to 10.6m INR.
What is Gennex Laboratories Ltd's Note Receivable growth rate?
Note Receivable CAGR 3Y
52%
Over the last year, the Note Receivable growth was -5%. The average annual Note Receivable growth rates for Gennex Laboratories Ltd have been 52% over the past three years .
